Amy Tillman, M.S., joined Statistics Collaborative, Inc. (SCI) in 2013. She is a member of the American Statistical Association, the Washington Statistical Society, Mu Sigma Rho, the National Statistics Honor Society, and the Society for Clinical Trials.
At SCI, Ms. Tillman has contributed to clinical trials in several areas, including neurodegenerative diseases, inherited retinal diseases, pediatric indications, renal cell carcinoma, type 2 diabetes, HIV, malaria, gonorrhea, and Alzheimer’s disease. She has served as project manager and independent reporting statistician for several Phase 2 and Phase 3 trials.
Ms. Tillman prepares and audits CDISC-compliant ADaM datasets and documentation. She coordinated and managed programming efforts for a final statistical analysis, prepared ADRGs for FDA submission, and performed analyses for the FDA and EMA at request. At the FDA Advisory Committee for inherited retinal diseases caused by mutations in the RPE65 gene, Ms. Tillman was the statistical back-room lead. This Phase 3 trial evaluating the efficacy and safety of Voretigene Neparvovec (Luxturna) was the first FDA-approved gene therapy for a genetic disease; the trial was a co-recipient of the 2017 Trial of the Year Award by the Society for Clinical Trials.
At SCI, she supervises biostatistical staff, trains staff on CDISC ADaM standards, and serves on the committee to develop best practices for programming and validation in R.
She received her B.S. cum laude in Mathematics with a minor in Statistics from the University of Georgia (2010) and her M.S. in Statistics with a quantitative certificate in Fisheries Science from Virginia Polytechnic Institute and State University (2012).
To contact SCI about a potential project, please call us at 202.247.9700 or click below.
Statistics Collaborative is experencing a business interruption due to circumstances beyond our control. Please call our main company phone number for details and updates.